OPEN: 2027 IMS Translational Research Award. Full applications due January 29, 2027 at 11:59 p.m. EST.
International — IMS / Riney Foundation 2027 Translational Research Grants ($175,000–$250,000; January 29 EST)
2027 IMS Translational Research Award. $175,000–$250,000 USD for an individual investigator's initial research project award, including institutional overhead up to 8%. Second-year support may be considered separately following research progress and available funding; no unconditional two-year ceiling is established. Due January 29, 2027 at 11:59 p.m. EST; specific investigator qualifications and award restrictions apply.
Funding$175,000–$250,000 USD for an individual investigator's initial research project award, including institutional overhead up to 8%. Second-year support may be considered separately following research progress and available funding; no unconditional two-year ceiling is established.
DeadlineOPEN. Full application due January 29, 2027 at 11:59 p.m. Eastern Standard Time. The current controlling program documentation and IMS announcement agree on this deadline.
Last verified2026-11-06
Required next actionCheck eligibility (Established faculty member or other scientist with M.D. and/or Ph.D. conducting translational research relevant to multiple myeloma or other plasma cell dyscrasias. Researchers entering myeloma from other fields may qualify. A Principal Investigator or co-investigator must be an IMS member; previously funded investigators cannot apply with an unrelated new proposal.) and controlling instructions https://www.myelomasociety.org/grants/international-myeloma-society-ims-and-paula-and-rodger-riney-foundation-translational-research-grant/; register/login to https://myelomasociety.flexigrant.com/; prepare Institution-approved application, five-page research plan (specific aims, significance, innovation, preliminary data, methods), references (up to 25), investigator CV/biosketch, eligibility and translational endpoint statement, itemized budget and justification. Submit complete application by January 29, 2027 at 11:59 p.m. Eastern Standard Time.
Broad Eligibility
Established faculty member or other scientist with M.D. and/or Ph.D. conducting translational research relevant to multiple myeloma or other plasma cell dyscrasias. Researchers entering myeloma from other fields may qualify. A Principal Investigator or co-investigator must be an IMS member; previously funded investigators cannot apply with an unrelated new proposal.
Atlas Analysis
Official 2027 IMS 2027 IMS Translational Research Award guidelines, October 15 2026 funder announcement, and live IMS grant application portal reviewed November 6, 2026. Distinct 2027 award mechanism IMS-RINEY-TRANSLATIONAL-2027. Applicant funding $175,000–$250,000 USD for an individual investigator's initial research project award, including institutional overhead up to 8%. Second-year support may be considered separately following research progress and available funding; no unconditional two-year ceiling is established. Research scope Investigator-initiated translational research into prevention, early detection, diagnosis and treatment of multiple myeloma and related plasma cell disorders, including biomarkers, molecular assays, imaging, clinical applications and novel therapies. Controls: Eligible budget elements may include approved research salary support, lab supplies, services and travel. Essential equipment requires special justification. Institutional overhead is capped at 8% and included within the individual grant amount. Progress reports are required at six months and the end of the funded year; subsequent year extension is not automatic. The official program page does not state a universal required matching contribution. Duplicate search included all published and unpublished WordPress grant titles and sources for IMS, Myeloma Society, Riney, Plasma Cell, Translational Research and Career Development; no same track-year solicitation found.
Grant opportunity
The 2027 IMS Translational Research Award is a genuine competitive funding opportunity from the International Myeloma Society (IMS) and, for the translational mechanism, the Paula and Rodger Riney Foundation. The newly open 2027 cycle supports Investigator-initiated translational research into prevention, early detection, diagnosis and treatment of multiple myeloma and related plasma cell disorders, including biomarkers, molecular assays, imaging, clinical applications and novel therapies.
Applicant-level funding and deadline
$175,000–$250,000 USD for an individual investigator’s initial research project award, including institutional overhead up to 8%. Second-year support may be considered separately following research progress and available funding; no unconditional two-year ceiling is established. Applications are due January 29, 2027 at 11:59 p.m. Eastern Standard Time. This is a full research application, not a preliminary registration or an invitation to government vendor procurement. The combined funding pool announced for both IMS mechanisms exceeds $3 million, separate from individual award limits.
Eligibility and research fit
Established faculty member or other scientist with M.D. and/or Ph.D. conducting translational research relevant to multiple myeloma or other plasma cell dyscrasias. Researchers entering myeloma from other fields may qualify. A Principal Investigator or co-investigator must be an IMS member; previously funded investigators cannot apply with an unrelated new proposal. Applicants should follow the precise official track-specific restrictions, including research appointment, mentorship, host requirements and IMS membership where applicable.
Allowable costs and restrictions
Eligible budget elements may include approved research salary support, lab supplies, services and travel. Essential equipment requires special justification. Institutional overhead is capped at 8% and included within the individual grant amount. Progress reports are required at six months and the end of the funded year; subsequent year extension is not automatic. The official program page does not state a universal required matching contribution. Applications undergo scientific review, and only research aligned with the stated award purpose qualifies.
Application instructions
Submit via the official IMS grant management portal (FlexiGrant). Registration for a grant-portal account is required. The track-specific application packet requires: Institution-approved application, five-page research plan (specific aims, significance, innovation, preliminary data, methods), references (up to 25), investigator CV/biosketch, eligibility and translational endpoint statement, itemized budget and justification. Read the controlling IMS 2027 award instructions and October 15, 2026 funding announcement before submission. Last verified: November 6, 2026.
Source verificationReferenced source · www.myelomasociety.orgAtlas last verified this record 2026-11-06. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
